Published in Cardiol Rev on August 06, 2014
Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives. Curr Heart Fail Rep (2017) 0.75
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med (1996) 12.77
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (1999) 11.26
The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med (1997) 10.68
An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest (1990) 10.35
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet (1999) 10.07
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med (1987) 8.77
HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail (2010) 6.37
Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med (2002) 5.50
Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA (2003) 5.09
A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med (2001) 4.07
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med (2008) 3.98
Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. Clin Pharmacol Ther (2012) 3.91
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med (2001) 3.44
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation (2002) 3.34
Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA (2005) 3.16
Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med (2003) 2.83
A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem (1999) 2.78
A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A (2006) 2.72
Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature (1999) 2.55
Angiotensin-converting enzyme inhibitors. Circulation (1998) 2.10
A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J (2000) 1.96
Diuretic therapy. N Engl J Med (1998) 1.86
Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm (2011) 1.85
Data storage and DNA banking for biomedical research: informed consent, confidentiality, quality issues, ownership, return of benefits. A professional perspective. Eur J Hum Genet (2003) 1.69
The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem (2002) 1.63
A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail (2003) 1.60
Association of β-blocker exposure with outcomes in heart failure differs between African American and white patients. Circ Heart Fail (2012) 1.55
Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics (2005) 1.53
Pharmacogenetics of the human beta-adrenergic receptors. Pharmacogenomics J (2006) 1.49
Electronic health record design and implementation for pharmacogenomics: a local perspective. Genet Med (2013) 1.48
Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol (2008) 1.46
Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol (2009) 1.42
An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail (2003) 1.41
Polymorphism in the beta(1)-adrenergic receptor gene and hypertension. Circulation (2001) 1.35
Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics (2003) 1.32
An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail (2009) 1.25
Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol (2006) 1.19
Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature. J Cardiovasc Pharmacol (1998) 1.16
Adrenergic signaling polymorphisms and their impact on cardiovascular disease. Physiol Rev (2010) 1.15
Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol (2004) 1.14
ABC of heart failure. Clinical features and complications. BMJ (2000) 1.11
Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. Clin Pharmacol Ther (2011) 1.11
The pathophysiology of heart failure. Cardiovasc Pathol (2012) 1.09
Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics (2005) 1.04
Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenet Genomics (2007) 1.01
Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther (2005) 1.00
Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics (2008) 0.97
Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovasc Drugs Ther (2010) 0.95
Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms. PLoS One (2012) 0.94
The impact of beta-adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure. Eur J Heart Fail (2005) 0.93
Adrenergic-pathway gene variants influence beta-blocker-related outcomes after acute coronary syndrome in a race-specific manner. J Am Coll Cardiol (2012) 0.92
Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. Circ Arrhythm Electrophysiol (2012) 0.90
Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients. Br J Clin Pharmacol (2011) 0.90
Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure. Pharmacogenomics J (2009) 0.89
Pathophysiology of congestive heart failure. Rev Cardiovasc Med (2003) 0.89
Angiotensin converting enzyme insertion/deletion polymorphism and the risk of heart failure in hypertensive subjects. Eur Heart J (2004) 0.88
Carvedilol blocks beta2- more than beta1-adrenoceptors in human heart. Cardiovasc Res (2005) 0.87
Pharmacogenetic associations of MMP9 and MMP12 variants with cardiovascular disease in patients with hypertension. PLoS One (2011) 0.87
Genetic polymorphism, medical therapy and sequential cardiac function in patients with heart failure. Arq Bras Cardiol (2008) 0.85
Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. Eur J Heart Fail (2012) 0.85
Beta-adrenergic blockers in heart failure: review of mechanisms of action and clinical outcomes. J Cardiovasc Pharmacol Ther (2004) 0.85
Pharmacogenetics in chronic heart failure: new developments and current challenges. Curr Heart Fail Rep (2012) 0.84
Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail (2012) 0.84
Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am J Med (1999) 0.83
Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein inhibitors on digoxin serum concentration in congestive heart failure patients. Pharmacol Rep (2007) 0.82
Genetic mapping of adrenergic receptor genes in humans. J Mol Med (Berl) (1995) 0.82
The problem of polypharmacy in heart failure. Curr Cardiol Rep (2006) 0.81
To replicate or not to replicate: the case of pharmacogenetic studies: Establishing validity of pharmacogenomic findings: from replication to triangulation. Circ Cardiovasc Genet (2013) 0.81
Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new. J Card Fail (2012) 0.81
The genetics of loop diuretic effects. Pharmacogenomics J (2010) 0.80
Loop diuretic therapy in heart failure: the need for solid evidence on a fluid issue. Clin Cardiol (2010) 0.80
Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients. Clin Pharmacol Ther (2012) 0.79
Genetic variants of the renin-angiotensin-aldosterone system and reverse remodeling after cardiac resynchronization therapy. J Card Fail (2012) 0.78
Interaction of digitalis-like compounds with p-glycoprotein. Toxicol Sci (2012) 0.78
ACE insertion/deletion, but not -240A>T polymorphism, modulates the severity in heart failure. J Investig Med (2008) 0.77
Pharmacogenetics and healthcare outcomes in patients with chronic heart failure. Eur J Clin Pharmacol (2012) 0.77
Post-mortem ABCB1 genotyping reveals an elevated toxicity for female digoxin users. Int J Legal Med (2011) 0.76
A Canadian context for the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF) trial. Can J Cardiol (2008) 0.76
Patients with asthma who do not fill their inhaled corticosteroids: a study of primary nonadherence. J Allergy Clin Immunol (2007) 1.67
High rates of false-positive hepatitis C antibody tests can occur after left ventricular assist device implantation. ASAIO J (2013) 1.62
Differing effects of metformin on glycemic control by race-ethnicity. J Clin Endocrinol Metab (2014) 1.61
Factors predicting inhaled corticosteroid responsiveness in African American patients with asthma. J Allergy Clin Immunol (2010) 1.57
Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol (2011) 1.56
Safety of anticoagulation reversal in patients supported with continuous-flow left ventricular assist devices. ASAIO J (2015) 1.39
Gastrointestinal bleeding with the HeartMate II left ventricular assist device. J Heart Lung Transplant (2012) 1.38
Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Saf (2009) 1.18
A cluster-randomized trial to provide clinicians inhaled corticosteroid adherence information for their patients with asthma. J Allergy Clin Immunol (2010) 1.16
Ventricular assist devices: is destination therapy a viable alternative in the non-transplant candidate? Curr Heart Fail Rep (2013) 1.15
Comparing methods for identifying patients with heart failure using electronic data sources. BMC Health Serv Res (2009) 1.12
Effect of "energy drink" consumption on hemodynamic and electrocardiographic parameters in healthy young adults. Ann Pharmacother (2009) 1.09
Race-ethnic differences in factors associated with inhaled steroid adherence among adults with asthma. Am J Respir Crit Care Med (2008) 1.07
Relationship between recent short-acting beta-agonist use and subsequent asthma exacerbations. Ann Allergy Asthma Immunol (2008) 1.04
Insulin resistance is associated with significant clinical atherosclerosis in nondiabetic patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol (2013) 1.02
Stroke while on long-term left ventricular assist device support: incidence, outcome, and predictors. ASAIO J (2014) 0.95
Dual-specificity phosphatase 1 as a pharmacogenetic modifier of inhaled steroid response among asthmatic patients. J Allergy Clin Immunol (2010) 0.94
Basic concepts and potential applications of genetics and genomics for cardiovascular and stroke clinicians: a scientific statement from the American Heart Association. Circ Cardiovasc Genet (2015) 0.93
Adrenergic-pathway gene variants influence beta-blocker-related outcomes after acute coronary syndrome in a race-specific manner. J Am Coll Cardiol (2012) 0.92
Impact of continuous-flow left ventricular assist device support on right ventricular function. J Heart Lung Transplant (2013) 0.91
Non-cardiac surgery in patients on long-term left ventricular assist device support. J Heart Lung Transplant (2012) 0.86
Pharmacogenetics in chronic heart failure: new developments and current challenges. Curr Heart Fail Rep (2012) 0.84
Policies and events affecting prescription opioid use for non-cancer pain among an insured patient population. Pain Physician (2014) 0.83
Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality. Am J Cardiol (2012) 0.83
Early management of patients with acute heart failure: state of the art and future directions--a consensus document from the SAEM/HFSA acute heart failure working group. Acad Emerg Med (2014) 0.82
Patients with low compared with high body mass index gain more weight after implantation of a continuous-flow left ventricular assist device. J Heart Lung Transplant (2012) 0.81
Interaction between PPARA genotype and beta-blocker treatment influences clinical outcomes following acute coronary syndromes. Pharmacogenomics (2008) 0.81
Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association. Circulation (2015) 0.81
Enhancing Literacy in Cardiovascular Genetics: A Scientific Statement From the American Heart Association. Circ Cardiovasc Genet (2016) 0.80
Impact of pre-implant amiodarone exposure on outcomes in cardiac transplant recipients. Heart Fail Rev (2015) 0.80
Comparison of renal predictors for in-hospital and postdischarge mortality after hospitalized heart failure. J Cardiovasc Med (Hagerstown) (2012) 0.79
ACCF/AHA/HFSA 2011 survey results: current staffing profile of heart failure programs, including programs that perform heart transplant and mechanical circulatory support device implantation. J Card Fail (2011) 0.77
Genetic variation in B cell-activating factor of the TNF family (BAFF) and asthma exacerbations among African American subjects. J Allergy Clin Immunol (2012) 0.77
Comparison of β-blocker effectiveness in heart failure patients with preserved ejection fraction versus those with reduced ejection fraction. J Card Fail (2013) 0.77
Relationship of Loop Diuretic Dosing and Acute Changes in Renal Function during Hospitalization for Heart Failure. J Clin Exp Cardiolog (2011) 0.77
Management of aortic valve insufficiency in patients supported by long-term continuous flow left ventricular assist devices. Ann Thorac Surg (2012) 0.76
Race and association of angiotensin converting enzyme/angiotensin receptor blocker exposure with outcome in heart failure. J Cardiovasc Med (Hagerstown) (2015) 0.75
Patient characteristics and participation in a genetic study: a type 2 diabetes cohort. J Investig Med (2014) 0.75
Relationship of tricuspid repair at the time of left ventricular assist device implantation and survival. Int J Artif Organs (2014) 0.75
Acute intravenous infusion of an adenosine regulating agent improves left ventricular function in dogs with advanced heart failure. Cardiovasc Drugs Ther (2013) 0.75
Progress toward genetic tailoring of heart failure therapy. Curr Opin Mol Ther (2010) 0.75
Dosing of vancomycin in patients with continuous-flow left ventricular assist devices: a clinical pharmacokinetic analysis. Int J Artif Organs (2014) 0.75
Heart Rate and V˙O2 Concordance in Continuous-Flow Left Ventricular Assist Devices. Med Sci Sports Exerc (2016) 0.75
Challenges with Percent Predicted Maximum VO2 in Patients with Heart Failure. Med Sci Sports Exerc (2017) 0.75
Effect of Preoperative Albumin Levels on Outcomes in Patients Undergoing Left Ventricular Device Implantation. ASAIO J (2015) 0.75
Extremes of body mass index do not impact mid-term survival after continuous-flow left ventricular assist device implantation. J Heart Lung Transplant (2012) 0.75
Myoglobin and troponin I elevation predict 5-year mortality in patients with undifferentiated chest pain in the emergency department. Am Heart J (2008) 0.75
Assessment of the heart failure pharmacotherapy of patients with continuous flow left-ventricular assist devices. Int J Artif Organs (2012) 0.75
Caution with beta1-adrenergic receptor genotyping. Clin Pharmacol Ther (2004) 0.75